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Abstract  
 
Wig-1 is a transcriptional target of the tumor suppressor p53. p53 is activated by cellular 
stress and can induce a wide variety of responses. Some – like apoptosis – follow upon severe 
damage, while milder damage results in outcomes such as cell cycle arrest and DNA repair. 
Yet other p53 functions rely on physiological p53 levels. p53 mainly exerts its functions 
through inducing the transcription of target genes, hence in order to understand the function 
of p53 one must understand the function of these targets. Wig-1 was identified as a p53 target 
more than ten years ago, and was found to be a double stranded RNA binding protein. Apart 
from that, however, its function has remained elusive. In this work we demonstrate that Wig-1 
regulates mRNA stability through binding to so-called AU-rich elements in 3’UTRs, and we 
identify p53 as well as N- and c-Myc as its targets. We also report that Wig-1 knockout 
causes early embryonic lethality in mice, probably due to dysregulation of Wig-1 targets such 
as Myc. Thus we show that p53, through Wig-1, can activate Myc and possibly other pro-
survival targets. This activation may represent a way of facilitating for cells to recommence 
cycling after a repaired damage. Simultaneously, increased Wig-1 sensitizes the cell to any 
remaining damage by also stabilizing the p53 mRNA. In conclusion, we have found that the 
p53 target Wig-1 regulates mRNA stability through AU-rich elements. We propose a novel 
mechanism by which p53, through Wig-1, can tweak the cell milieu toward survival. 
 
 
 
Populärvetenskaplig sammanfattning 
 
I den här avhandlingen har vi beskrivit funktionen av Wig-1, en gen som aktiveras av den 
kända tumörsuppressorn p53. p53 hindrar celler från att förvandlas till cancerceller, framför 
allt genom att aktivera andra gener som sedan har olika anti-cancer-funktioner i cellen. 
Aktiverat p53 kan antingen leda till att cellen tar en paus och lagar eventuell skada (vilket ofta 
händer vid mildare stress) eller att den dör (om den är allvarigt skadad). För att riktigt förstå 
hur p53 fungerar är det viktigt att förstå funktionen av p53:s målgener, och därför har vi 
studerat funktionen av Wig-1. Vi har funnit att Wig-1 kan reglera stabiliteten av vissa s.k. 
mRNA i cellen, och därmed kan Wig-1 reglera nivåerna av de proteiner som kodas för i dessa 
mRNA. Eftersom det framförallt är proteiner som utför de olika funktionerna i cellen, kan 
Wig-1 påverka hur en cell reagerar på t.ex. stress. Vi har funnit att Wig-1 på detta sätt kan 
stabilisera p53, och dessutom stabilisera Myc, en gen som är känd för att driva på celltillväxt 
och för att inducera cancer. Fyndet att Wig-1 reglerar Myc antyder att Wig-1 kan bidra till att 
celler överlever och delar sig. Dessutom har vi funnit att möss som helt saknar Wig-1 dör 
väldigt tidigt under embryonalutvecklingen, förmodligen för att mRNA som i vanliga fall 
kontrolleras av Wig-1 inte längre regleras som de ska. Även dessa resultat visar på en viktig 
roll för Wig-1 i cell-överlevnad. Vi tror att Wig-1 kan fungera så att den påverkar balansen i 
p53:s reaktion på mildare stress i riktning mot ett svar som möjliggör att cellen kan ta en paus, 
reparera eventuell skada, och sedan fortsätta att leva och dela sig – i stället för att dö av 
aktiverat p53. Eftersom Wig-1 stabiliserar p53 samtidigt som den stabiliserar faktorer som 
bidrar till tillväxt så kan Wig-1 också öka cellens beredskap om skadan inte lagats ordentligt.  
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Introduction 
 
What is cancer? 
 
This question is obviously a handful to answer. In the short version, cancer is either 
uncontrolled and untimely cell growth, or prolonged survival of cells that should be dying, or 
both. A cell should know when, how much, and how many times to divide, it should respect 
borders, and it should die if so instructed. Normal cells know how to behave from integrating 
a myriad of signals and factors, some inherent to the particular cell type and some based on 
external circumstances – contacts with neighboring cells and the local environment but also 
signals from far away, mediated through the blood stream. In order to turn into a cancer cell, 
the cell has to render itself insensitive to these signals and factors. They achieve the escape 
from control through acquiring a number of traits, elegantly summarized by Hanahan and 
Weinberg in their seminal paper “The Hallmarks of Cancer”1. The cell can overcome the 
barriers represented by these hallmarks in various ways. They can activate genes that promote 
growth, invasion, and angiogenesis (genes that we know as oncogenes), or inactivate genes 
that prevent these events (genes known to us as tumor suppressor genes). This (in-)activation 
can occur by genetic changes such as mutation of a gene, gene amplification or deletion, or by 
modifying chromatin (epigenetic changes). Sometimes, the inactivation of one single gene 
can contribute to overcoming several of Hanahan and Weinberg’s hallmarks. Such is the case 
for p53.* 
 
 
p53 
 
One of the main characters of this thesis will be p53, arguably the most studied gene in 
history. Its most important biological role is to prevent transformation of normal cells into 
cancer cells. Simple as that may sound, the function of p53 is extremely complex. p53 serves 
as the hub in a vast network – or rather in several different networks – receiving a flood of 
input on potential threats to the cell and responding in ways designed to keep the cell from 
turning cancerous. p53 has been bestowed the name “the guardian of the genome”2, a name 
that reflects the important job p53 does protecting us from cancer. This protective role is 
demonstrated by the fact that virtually all tumors have inactivated the p53 pathway in one 
way or another – often by p53 mutation; something between 30-50% of human tumors carry 
mutated p53 (www-p53.iarc.fr; p53.free.fr). Additionally, p53 mutations are implied in 
inherited cancer since the highly tumor prone Li-Fraumeni syndrome is caused by germ line 
p53 mutations3 (reviewed in4). The tumor suppressive role of p53 is also shared with our 
murine cousins – mice lacking p53 rapidly develop tumors and die before nine months of age, 
typically from lymphoma and sarcoma5.                                                         * At this point I will introduce my footnotes, which I have included for those brave few who might attempt 
reading this thesis without being familiar with scientific jargon. As an introduction: this thesis deals a lot with 
transcription factors and mRNA regulation. In the nucleus, a gene is transcribed into RNA – a process regulated 
by transcription factors. This RNA can be an mRNA, which is then exported to the cytoplasm where it is 
translated by the ribosome into a protein, which carries out functions in the cell. The RNA can also be some 
other kind of RNA (like a microRNA) that, after some processing, carries out its function as an RNA molecule.   
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 p53 was identified in 1979 by Lane and others6-9 as a protein bound to the SV40 virus Large 
T antigen, and was first thought to be an oncogene – the gene subsequently cloned10-12 was a 
mutated version of p53 that could function as a dominant negative to the wild type (reviewed 
in13). The misunderstanding was resolved when wild type p53 was found to be frequently 
deleted in colorectal cancer14,  suggesting that it was a tumor suppressor. This suggestion was 
confirmed by a number of studies in human and rodent cells in vivo and in vitro (reviewed 
in13). 
 
Since the discovery more than 30 years ago the knowledge on p53 has virtually exploded15. 
Judging from the literature today, p53 is involved in any and every pathological and 
physiological process imaginable, from cancer to embryonic development and aging, passing 
by any number of diseases on the way. All I can manage here is to briefly brush the surface of 
p53 knowledge – starting out with one fundamentally important aspect of p53: It is a protein 
that is activated by stress. 
 
 
p53 is activated by stress 
 
In healthy unstressed cells, p53 levels are kept low, almost undetectable. After cellular stress 
p53 accumulates dramatically, largely due to stabilization of the p53 protein. This 
stabilization is mainly achieved by blocking the interaction between p53 and its negative 
regulator Mdm2 – a process described in detail below. p53 can be activated by a diverse array 
of signals including DNA damage, oncogene activation, nutrient deprivation, hypoxia, and 
ribosomal stress. Also the very low presence of p53 in unstressed cells can exert functions, 
and these functions may be radically different from those initiated by high stress-induced p53 
levels (reviewed in16-18). Here, I will limit the discussion to the p53 activators DNA damage 
and oncogene activation. 
 
DNA damage, caused by, for instance, radiation or cytostatic drugs, leads to the accumulation 
and activation of protein complexes at the site of damage. These protein complexes in turn 
activate the kinases* ATM or ATR. ATM is activated by double stranded (ds) DNA breaks 
and ATR is activated by stalled replication forks# caused by single stranded (ss) DNA breaks 
or other DNA damage. Once activated, ATM and ATR will phosphorylate and activate the 
kinases Chk2 and Chk1, respectively, in that way amplifying the signal. Chk2 or Chk1, 
together with ATM or ATR will also phosphorylate sites on p53, which prevents the 
interaction between p53 and Mdm2 – in that way preventing the negative regulation of p53 
(see below) (reviewed in19).  
 
Another evident threat to the cell is the activation of oncogenes – genes that induce and/or 
promote cell proliferation. Different oncogenes can affect proliferation through many                                                         * A kinase is a protein that phosphorylates – i.e. puts phospho-groups on – other things.  # A stalled replication fork has nothing to do with lazy eating but is instead a term to explain that during DNA 
replication – copying of the DNA – the replication machinery stops, usually because it encounters some problem 
(a DNA break or some other DNA damage, for example) and doesn’t know what to do about it.  
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different mechanisms, but in the end they all result in the activation of growth promoting 
transcription factors, mainly of the E2F family. The E2Fs will then activate many genes 
involved in cell proliferation – in short; they work as powerful gas pedals for the cell. As such 
they also need to come with an emergency brake – a function carried out by p14ARF. 
p14ARF is a transcriptional target of E2F20 (and of some other growth promoting 
transcription factors as well, for good measure). The p14ARF protein binds to Mdm2, and this 
binding will prevent the latter from binding to p5321,22 (reviewed in23). While Mdm2 is thus 
otherwise engaged, p53 is free to exert its functions.  
 
In a combination of the two above-mentioned mechanisms, activated oncogenes also induce a 
process known as the DNA damage response (DDR). Activated oncogenes drive deregulated 
replication, which causes stalled replication forks and double stranded DNA breaks – in turn 
inducing the ATR/ATM pathway of p53 activation24,25.  
 
See figure 1 for an illustration. 
 
 
p53 function 
 
How can any one protein have such profound impact on the cell as p53 apparently has? The 
main and most well studied function of p53 is that of a transcriptional activator– it activates 
the transcription of target genes, which will result in the production of other proteins and 
microRNAs. These p53 targets will in turn execute the p53 functions – and activation of a 
different subset of targets can alter the nature of the p53 response. The importance of 
transactivation for the ability of p53 to prevent transformation is underlined by the high 
mutation frequency in the p53 DNA binding domain, which is necessary for the 
transactivating activity (reviewed in26). When functioning as a transcriptional activator, a p53 
tetramer binds DNA through its DNA binding domain. It binds to the p53 consensus response 
element, which is made up of two tandem copies of the motif “RRRCWWGYYY” separated 
by a spacer of 0 to 13 base pairs (“R” represents purines*, “W” represents adenine or thymine, 
and “Y” represents pyrimidines#) (reviewed in27,28). p53 recruits the general transcription 
machinery to the promoter-enhancer region of its target genes, thus inducing their 
transcription29,30 (reviewed in 31). 
 
Apart from being a transcriptional activator, p53 can also work as a transrepressor inhibiting 
the transcription of target genes – a classical example is that of the anti-apoptotic bcl-2 gene32. 
There appears to be multiple ways through which p53 can repress transcription, some of 
which are mediated through direct binding of p53 to DNA (reviewed in33).  
 
Further, p53 can act independently of transcription. It can relocalize to mitochondria and 
directly affect the apoptotic process there34 (see below for more on apoptosis) (reviewed in35). 
                                                        * Purines: Adenine and Guanine # Pyrmidines: Thymine and Cytosine  
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Further, p53 seems to be directly involved in RNA binding and microRNA processing36 (see 
below for details).  
  
 
 
Figure 1: Overview of inputs to p53 and p53 responses, with examples of target genes. See text for details.  
 
 
Outcomes of p53 activation 
 
p53 induces cell cycle arrest and apoptosis 
Once p53 has been activated and in turn has induced the transcription of a set of target genes 
– then what happens? The list of possible outcomes of p53 activation is constantly growing, 
but let’s start with the classics – apoptosis and cell cycle arrest. Apoptosis is the process of 
programmed cell death – cellular suicide on command. Cell cycle arrest is somewhat less 
dramatic – the cell stops in its division program, to check and repair any potential damage. 
There are fewer p53 target genes involved in cell cycle arrest than apoptosis, the two main 
players here being p2137 and 14-3-3σ38 (reviewed in39). The p21 protein halts the cell cycle 
primarily through binding to and inhibiting the actions of cyclin dependent kinase (CDK) 2. 
CDK2 functions in a complex with cyclin E to enable the cell to pass the restriction point of 
the cell cycle, allowing the cell to proceed from the gap 1 (G1) phase to the synthesis (S) 
phase and start replicating its DNA. CDK2/Cyclin E achieves the passing of the restriction 
point by phosphorylating pRb, a protein that once phosphorylated will release the E2F 
transcription factors. The E2Fs then activate target genes involved in – among other things – 
DNA replication. Once the cell has passed the restriction point it is committed to division and 
will, in the absence of any major catastrophes, complete a round of DNA replication and cell 
division (reviewed in40). 14-3-3σ instead inhibit the activity of Cdc2 (also known as CDK1) 
and by this prevents the G2/M transition (reviewed in41).  
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p53 can also induce the expression of a wide variety of genes involved in apoptosis. One 
example is the death receptor Fas42, which is important for the extrinsic pathway of apoptosis. 
This way of inducing apoptosis starts with activation of death receptors on the cell surface, 
which in turn activate caspase 8 that activates caspase 3, an effector caspase. Effector 
caspases then dismantle various cellular structures, destroying the cell in an orderly fashion. 
Among other pro-apoptotic p53 targets we find the BH3 proteins Bax43, PUMA44 and 
NOXA45, mainly involved in the intrinsic apoptotic pathway. This apoptotic pathway starts 
with the permeabilization of the outer mitochondrial membrane, releasing cytochrome c and 
other constituents of the so-called apoptosome, which once formed activates effector caspases 
such as caspase 3 and 6. Bax is involved in the permeabilization of the outer mitochondrial 
membrane, and PUMA and NOXA prevents the Bax inhibitor Bcl-2 from binding to Bax 
(reviewed in26,46).  
 
Evidence points to the p53 pro-apoptotic function as being the most important for tumor 
prevention. p21 knockout* mice, which have a severely impaired G1 arrest checkpoint, are not 
particularly tumor prone47, indicating that p53 dependent cell cycle is not required for tumor 
prevention. However, knock-in# mice carrying a p53 mutant that is unable to activate 
apoptosis but retains some ability to activate cell cycle arrest is less tumor prone than p53 null 
mice48, indicating that in the absence of apoptosis, cell cycle arrest can still contribute to 
tumor prevention.  
 
Among other p53 responses we find senescense – irreversible cell cycle arrest. The cell 
remains viable and metabolically active but will not divide even in the presence of all the 
appropriate signals. There are two types of senescence: Replicative senescence and premature 
senescence, and p53 is involved in both types. Replicative senescence is activated by 
telomeric signals telling the cell that its chromosome ends (telomeres), which are shortened 
every time the DNA is replicated, are now too short to sustain further division. The shortened 
telomeres activate the ATM and ATR DNA damage response, which in turn activates p53. 
Premature senescence is induced in response to signals including DNA damage, oncogene 
activation, or reactive oxygen species. There are several p53 targets involved in senescence, 
one of which is p21 (reviewed in49-51), and senescence induction is one way for p53 to prevent 
clonal expansion of insipient tumor cells52.   
 
p53 can also regulate differentiation – the process when a stem cell or progenitor cell turns 
into a more specialized cell type. Stem cells are often resistant to cell cycle arrest and 
apoptosis, making them risk factors for tumorigenesis42. p53 may promote differentiation of 
stem cells into cell types that can undergo cell cycle arrest and apoptosis, as well as prevent 
self-renewal of stem cells53 (reviewed in50,54). Further, p53 has been shown to be important 
for maintaining genomic stability in stem cells55. Efforts are being made to convert somatic 
cells§ to stem cells – so-called inducible pluripotent stem cells, iPSCs  (a process of great 
therapeutic interest, for example to generate compatible donor tissue), and the factors required                                                         
* A knockout mouse is a mouse lacking one gene, in this case p21. # A “knock-in” mouse refers to a mouse were a gene has been replaced by another; in this case the wild-type p53 
gene has been replaced by a mutant form of p53.  § Somatic cells: Every cell in the body except for germ cells and undifferentiated stem cells.   
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for this transition are often oncogenes or suspected oncogenes. As such they will activate p53 
through p14Arf. For that reason, p53 nullity contributes to the reprogramming of a somatic 
cell into a stem cell56 (reviewed in54). The role of p53 in embryonic development has also 
been studied. p53 seems dispensable for normal embryonic development since most mice that 
lack p53 develop without problems5, with the exception of a fraction of females that develop 
exencephaly*57,58. Additionally, p53 null mice have fewer offspring since they have lower 
levels of the p53 target LIF, important for implantation of the embryo into the uterus wall59. 
 
p53 can promote several forms of DNA repair, both through the transactivation of target 
genes (one example being GADD45 that is thought to remodel chromatin in order to make the 
DNA damage sites more accessible60) and through other mechanisms. p53 mainly promotes 
nucleotide- and base excision repair – where mismatches are identified, removed, and 
corrected – and mismatch repair, which repairs mistakes made during DNA replication. p53 
also regulates the dsDNA break repair mechanisms; homologous recombination and non-
homologous end joining. This regulation is exerted mainly transcription independent and is 
mainly negative, since these mechanism may increase genomic instability. In the case of 
severe damage such as dsDNA breaks, p53 is more likely to induce apoptosis. (Reviewed 
in50,61). 
 
Inhibition of angiogenesis – the process through which tumors ensure sufficient blood supply 
to bring them oxygen and nutrients is inhibited by p53 through the activation of anti-
angiogenic thrombospondin 162. 
 
Paradoxically, p53 can also induce genes involved in promoting survival. One of these genes 
is p21 – while being pro cell cycle arrest, p21 antagonizes apoptosis. The list also includes 
several antioxidant genes and genes involved in metabolism. The logic behind this surprising 
p53 function may be that the elimination of every cell ever exposed to any kind of stress is not 
desirable – while protecting us from getting cancer; it would lead to tissue degeneration 
(reviewed in16,63). 
  
p53 has been implicated in several other diseases apart from cancer, generally diseases 
connected to excessive cell death. These include diabetes, cell death after ischemia, and 
various neurodegenerative diseases such as Huntington, Parkinson, and Alzheimer (reviewed 
in16,17). Since p53 is able to eliminate cells through apoptosis and senescence and to induce 
differentiation, thus reducing stem cell populations, one is tempted to assume a role for p53 in 
aging as well. Initial studies in mice expressing constitutively active p53 also seemed to 
confirm this hypothesis64. However, subsequent mice models carrying an extra copy of p53 
but under control of its normal regulatory elements demonstrated that properly controlled p53 
did not induce aging. Instead it actually promoted longevity, largely by preventing 
tumorigenesis65. (Reviewed in66).  
 
See figure 1 for illustration. 
                                                         * Exencephaly: the brain is localized outside the skull  
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How does p53 choose? 
 
Since p53 has a huge number of target genes and an equally vast repertoire of possible 
responses at its service, how can it possible know what to choose? The simplest explanation is 
that the p53 affinity to its response elements decides – some genes harbor perfect p53 
consensus response elements located within favorable regions relative to the transcription 
start site, while other genes carry less well placed response elements with mismatches. In 
general, cell cycle arrest genes tend to have high-affinity response elements and pro-apoptotic 
genes have low-affinity response elements. Further, p53 abundance (more p53 favors a pro-
apoptotic response) and post-translational modifications of the p53 protein impact promoter 
selectivity. There are also several p53 cofactors that direct p53 to certain promoters. For 
example, the ASPP1 and 2 proteins direct p53 activity towards pro-apoptotic target genes 
(there is also an inhibitory family member, iASPP). Further, 53BP1 is involved in directing 
p53 to cell cycle arrest and DNA repair genes, and HZF biases p53 to activate cell cycle arrest 
associated genes. Taken together, these p53 rules-of-choosing suggest that low stress levels 
lead to a p53 response centering on arrest/repair/recovery while high stress induces apoptosis 
or senescence. (Reviewed in16,17,31,67). Basal p53 levels, in the absence of any stress, seem to 
be enough for induction of physiological responses, such as fertility, development, 
metabolism, and stem cell maintenance. On the other hand, p53 activation and the resulting 
increase in p53 levels are necessary for its tumor preventive effects. (Reviewed in15,67). See 
figure 2 for illustration. 
 
 
 
Figure 2: The various p53 responses to different amounts of stress, and the respective outcomes of those 
responses.  
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p53 family members and isoforms 
 
To make matters a bit more complicated, there isn’t just one of p53. p53 itself exists in 
several isoforms*. Some of these lack the N-terminal transactivation domain and can act as 
negative regulators of p53 function. Additionally, alternative splicing can give rise to different 
C-terminal variants. The exact function and physiological significance of these isoforms 
remain fairly unclear (reviewed in51). Apart from p53 itself, p53 also have two additional 
family members – p63 and p73. Although not as clearly connected to cancer as p53, there are 
several reports on the involvement of both p63 and especially p73 in cancer (reviewed in68,69). 
However, much interest has been directed to the obvious importance of these genes in normal 
development. p63 knockout mice die within hours after birth due to dehydration caused by 
lack of skin. These mice also have deficiencies in other epithelial tissues, and lack limbs70,71. 
p73 null mice are viable at birth, although a substantial amount of the pups die within the first 
three weeks of life. The homozygous knockouts have defect immune systems, have problems 
with chronic inflammation, and demonstrate brain malformations72. Both p63 and p73 come 
in a myriad of isoforms. Apart from the full-length isoforms (TA), they both exist in N-
terminally truncated variants (ΔN), lacking the transactivation domain. The ΔN isoforms can 
act as negative regulators of the TA isoforms. In addition, there are a number of C-terminal 
isoforms generated by alternative splicing. (Reviewed in68). 
 
 
Regulation of p53  
 
Since p53 is licensed to make life-and-death decisions, it goes without saying that this protein 
is tightly regulated. Immediately after stress, when p53 levels need to rise quickly, regulation 
of the protein is predominant. Transcriptional and post-transcriptional regulations are likely to 
be important for maintaining steady-state levels of p53 and for prolonged stress responses.  
 
 
Regulation of p53 at the protein level 
 
p53 is a labile protein that is continuously synthesized and degraded. Thus, p53 levels can 
quickly be increased simply by halting degradation – a process overseen by Mdm273-75. This 
negative regulator of p53 is an E3 ubiquitin ligase, binding to p53 and attaching the small 
protein ubiquitin to it76. Poly-ubiquitination marks p53 as a substrate for the proteasome, the 
cell’s protein degradation machine. Further, Mdm2 is itself a transcriptional target of p5377 – 
thus these two players are locked in a negative feedback loop where p53 activates the 
transcription of Mdm2 and Mdm2, once produced, induces the degradation of p53. Apart 
from being involved in p53 degradation, the Mdm2 binding to p53 also masks the p53 
transactivation domain, thus preventing p53 from activating target genes. (Reviewed in78,79). 
The importance of the negative regulation of Mdm2 on p53 is underlined by the fact that 
Mdm2 knockout mice die during embryonic development due to excessive apoptosis, a 
phenotype that is completely reversed if backcrossed to p53 null mice80,81. Additionally, as                                                         * Isoforms: different forms of one protein, generated from the same gene but processed into slightly different 
proteins that may or may not have different functions.   
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already mentioned, many of the ways to activate p53 after stress rely on interfering with the 
binding of Mdm2 to p53. Therefore it is perhaps not surprising that many tumors with wild-
type p53 instead have increased levels of Mdm2 – for example, Mdm2 amplifications are 
found in about one third of sarcomas82. 
 
Mdm2 also has family – MdmX (also known as Mdm4), an Mdm2 homologue that binds to 
p53 and prevents it from transactivating target genes. However, MdmX does not target p53 
for degradation and is not itself a p53 target. The interplay between Mdm2, MdmX and p53 is 
being studied intensely, but is as yet not completely elucidated. (Reviewed in79,83).   
 
Apart from Mdm2 and MdmX, there are many other proteins shown to bind and regulate p53 
in any variety of ways. On top of that, there are a vast number of different post-translational 
modifications such as phosphorylations, acetylations, ubiquitinations , methylations and so on 
that can affect p53 function, location, stability, choice of partners, and activity. The 
importance of these are yet debated, since knock-in mice mutated for individual 
phosphorylation sites show now evident phenotype (reviewed in79).   
 
 
Transcriptional regulation of p53 
 
The transcription of the p53 gene itself is in turn subject to regulation. The transcription 
factors PKCδ and HOXA5 have been implicated to transactivate84,85, and the proto-oncogene* 
Bcl-686 to transrepress, p53. Moreover, in vivo evidence suggests that p53 can regulate its 
own expression, since loss of one p53 allele in mice results in a fourfold reduction of p53 
mRNA and protein levels, as compared to p53 wild type mice87. 
 
Somewhat less is known about regulation of the p53 mRNA levels. This form of regulation – 
of p53 and of other genes – is the main focus of my thesis. Before discussing what is known 
about regulation of the p53 mRNA, I will spend some time describing mRNA regulation in 
general. 
 
 
Regulation mediated through mRNA  
 
An mRNA consists of the 5’untranslated region (UTR), the open reading frame (ORF) that 
codes for the protein, and the 3’UTR. The 5’UTR terminates in an atypically attached guanine 
mono phosphate to generate a structure known as the 5’cap, which protects the 5’UTR from 
degradation (reviewed in88). Additionally, the 5’cap and the proteins bound to it are 
recognized by the ribosome to initiate translation. The 5’UTR can also contain regulatory 
sequences, such as internal ribosomal entry sites (IRESes), which can provide alternative 
translation initiation. (Reviewed in89). The 3’UTR is protected from degradation by what is 
known as the polyA tail at its end. The polyA tail consists of approximately 250 adenosines90, 
which are not encoded in the corresponding gene, but are added by a 3’end processing 
machinery that recognizes polyadenylation signals in the nascent mRNA. The polyA tail is                                                         * Proto-oncogene: a potential oncogene carrying out its normal function in the cell. 
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bound by polyA-binding proteins (PABPs) that assist polyadenylation, export, translation and 
stability of the mRNA (reviewed in91,92). 
 
The steady state level of any given mRNA is the net difference of what is being produced and 
what is being degraded. In order for changes in transcription rates to quickly affect protein 
levels, the mRNA coding for that protein needs to be both transcribed and degraded at a high 
rate (that is, have a short half-life). Logically, mRNAs coding for proteins with important 
regulatory functions generally have the shortest half-lives, reflecting a need to quickly change 
the abundance of these proteins. mRNA degradation is thus an important process for 
controlling central regulatory functions in the cell. The removal of the protective 5’cap and 
the polyA tail are rate limiting for degradation to occur. These steps are required for the 
exonucleases* responsible for degradation to gain access to the mRNA ends. In mammalian 
cells, the main pathway for initiation of mRNA degradation seems to be through 
deadenylation. mRNA continuously loose their polyA tails, and once the tail has reached 
below a critical level (around 30-60 As), mRNA degradation commences. This process 
generally starts with hydrolysis of the 5’cap followed by 5’-3’ degradation mediated by the 
exonuclease Xrn1. In an alternative pathway the mRNA, after loss of the polyA tail, is 
degraded from the 3’end by the exosome. mRNA degradation mainly takes place in the 
cytoplasm, although the exosome can also be found in the nucleus. (Reviewed in93). In order 
to make mRNA degradation a regulated process, deadenylation cannot happen at the same 
rate for all mRNA – and indeed it does not! Most elements regulating deadenylation – and 
other aspects of mRNA degradation and translation efficiency – reside in the 3’UTR of the 
mRNA in question. The most well known factors to regulate mRNA stability and translation 
are microRNA (miRNA) and AU-rich elements (AREs). See figure 3 for an illustration. 
 
 
 
Figure 3: Factors regulating mRNA stability and translation efficiency 
 
                                                         * Exonucleases: nucleases that degrades from the ends, as opposed to endonucleases, that cut in internal part of 
an RNA. 
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AU-rich elements and the proteins that bind to them – and how they affect p53 
 
AU-rich elements are present in the 3’UTRs of certain mRNAs and consist of the element 
AUUUA in various constellations or regions of Us only94,95. AREs are found in five to eight 
% of the transcriptome*, generally in mRNAs of genes that need very precise control of their 
expression. Examples include genes encoding proteins regulating cell growth or response to 
external factors, such as c-Myc, N-Myc, cyclins, interferons, p53 and p21 (reviewed in94,95). 
AREs can mediate degradation both by increasing deadenylation and subsequent decay of the 
mRNA they reside in. Several exosomal subunits (for example PM-Scl-75), as well as the 5’-
3’ exonuclease Xrn1, can recognize and bind AREs. Both Xrn1 and PM-Scl-75 seem to be 
required for effective ARE-mediated decay (AMD). (Reviewed in93,96). Further, AREs can 
decrease the translation efficiency of the mRNA they reside in. Most factors reported to bind 
and regulate AREs affect the target mRNA negatively, by promoting degradation or inhibiting 
translation (a classical example being Tristetraproline (TTP)). There are also positive ARE 
regulators such as Human antigen R (HuR), and those that can act either positively or 
negatively, depending on the mRNA in question – for example AUF194,96. ARE-interacting 
proteins are important nodes of regulation, since they can potentially control the levels of 
many different mRNAs in the cell. (Reviewed in95,97). The 3’UTR of p53 harbors one U-rich 
region (18 continuous Us), and one additional ARE containing the AUUUA motif98,99, both of 
which are targeted for regulation by several ARE-binding proteins (ARE-BPs). The first 
reported factor affecting the p53 mRNA is a still unidentified 40 kDa protein that inhibits 
translation of p53 mRNA via the U-rich region100. In addition, the C. elegance protein GLD-1, 
related to the Quaking protein in mammals, binds to the 3’UTR of the C. elegance p53 
homologue CED-1 and represses its translation101. Further, HuR binds to the p53 AREs and 
increases p53 mRNA stability102 and translation98. However, the effect of HuR on p53 is 
complex, since a recent study of HuR knockout mice shows that HuR also can stabilize 
Mdm2 mRNA through an ARE, thus leading to decreased p53 protein levels103. See figure 4 
for an illustration of factors regulating the AREs in p53 mRNA. p53, being a tumor 
suppressor, may appear as a surprising target for ARE-mediated regulation. Most AREs are 
found in genes associated with increased proliferation, suggesting that positive ARE 
regulation would promote tumor growth, and vice versa – that negative ARE regulation would 
cause tumor suppression (reviewed in95,97). Consistent with this notion, several studies have 
shown that HuR is overexpressed and/or relocalized to the cytoplasm (where it is active in 
ARE regulation) in cancer104-107. Further, the ARE destabilizer TTP has been shown to act as 
a tumor suppressor108, and reduced TTP levels is a bad prognostic marker in breast cancer109. 
However, HuR can clearly also stabilize mRNAs involved in growth inhibition, such as 
p21110. Thus, ARE-mediated regulation is complex and may affect growth-inhibitory genes as 
well as growth-promoting ones. It is possible that other and yet to be identified regulatory 
pathways can enable selective regulation of ARE-containing mRNAs.  
 
 
 
                                                         * Transcriptome: Everything transcribed (all the RNA) in a given cell. Often used to mean mRNA specifically.  
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miRNAs and how they regulate p53 
 
microRNAs (miRNAs) and small interfering RNAs (siRNAs) are short RNAs (around 22 
nucleotides) that were recently disovered111 but are already widely recognized as important 
mRNA regulators. miRNAs are endogenous* RNAs transcribed as long miRNA precursors, 
while siRNA are either exogenous or produced endogenously by alternative pathways (known 
as endosiRNAs). miRNA precursos (termed pri-miRNA) are cleaved in the nucleus by the 
ribonuclease Drosha in a complex with DGCR8 and DDX5. The resulting, approximately 70 
nt long, pre-miRNA has a hairpin structure with a two nucleotide 3’end overhang, and is 
exported to the cytoplasm by Exportin-5. Once in the cytoplasm, it is recognized and cleaved 
by Dicer to yield a mature, double stranded miRNA. One of the strands of the mature miRNA 
is incorporated in the RISC complex containing an Ago protein. The miRNA then guides the 
RISC complex to target mRNAs by binding to partially complementary sequences in the 
3’UTRs of these mRNAs. The binding of targets leads to Ago-dependent inhibition of 
translation or exonucleolytic mRNA degradation. siRNA are recognized by Dicer and 
similarly incorporated into RISC complexes, but unlike most miRNA they are perfectly 
complementary to the target mRNA and directs endonucleolytic cleavage and subsequent 
degradation of the target mRNA. The 3’UTR of one particular gene can have many different 
miRNA binding sites, and one miRNA typically has many different targets112-114. The p53 
3’UTR is regulated by several miRNA, namely miR-125a95, miR-125b115,116, miR-504117, the 
miR-30 family118, and miR-1285119. Moreover, miR-125b was shown to target upstream 
regulators of p53, leading to decreased transcription of the p53 gene as well115. See figure 4 
for an illustration of miRNA regulating p53 mRNA. Various miRNAs have been indicated 
both as tumor suppressors (such as the miR-34 family) and oncogenes (such as the miR-17-92 
cluster) (reviewed in114). However, miRNA function may be selected against during 
transformation since global miRNA levels often are decreased in cancer120,121.  
 
Figure 4: p53 mRNA and the factors that regulate it. Asterisk indicates a C. elegance protein. See text for details                                                         * Endogenous – produced in the cell; as opposed to exogenous meaning that someone (like a scientist) put it 
there.  
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Interplays between miRNA and AREs 
 
Nature seems to favor complexity whenever possible, so it is perhaps not surprising that 
ARE-mediated and miRNA-mediated effects on 3’UTRs are linked in many ways. A high AU 
content around the miRNA target site increases the likelihood of miRNA-mediated mRNA 
degradation, and miRNA target sites are often located in the vicinity of AREs.122,123. In 
addition, there are several examples of collaboration between AMD and microRNAs124-126. 
 
 
miRNA, AREs, and development 
 
ARE-mediated regulation can play an important role during embryonic development, 
demonstrated by the embryonic lethal phenotype of the ARE-BP HuR, which is caused by 
deregulation of HuR targets127. AREs are also important in late stage oocytes and in the early 
embryo, where they regulate stability of the maternal mRNAs that need to be retained until 
the embryo genome is activated and transcription of embryo genes can commence (reviewed 
in128). The importance of miRNA during development is illustrated by the early embryonic 
lethal phenotype in Dicer129 and DGCR8130 knockout mice. Further evidence is found in the 
early post-natal lethality of mice knockout for the miR-17-92 cluster and the embryonic lethal 
phenotype of the simultaneous knockout of miR-17-92 and the paralogue* miR-106b-25 
cluster131. Also interesting in terms of RNA in development are the piRNAs, germ cell 
specific small miRNA-like RNAs. The piRNAs associate with the Piwi subclass of Argonaut 
proteins and are essential for germ cell development. Their function is so far mainly 
unknown, but may involve silencing of transposons# (reviewed in132).  
 
 
Post-transcriptional regulation of p53 through the 5’UTR and ORF 
 
p53, being ever carefully regulated, is subject to control through its 5’UTR and ORF in 
addition to its 3’UTR. The p53 5’UTR is GC-rich and forms a stem-loop that hinders 
ribosome access during cap-dependent translation initiation. Cap-independent translation 
initiation using an IRES can overcome this difficulty133. The ribosomal protein RPL26 can 
enhance, and the protein Nucleolin can inhibit, p53 translation134. Further, the p53 5’UTR is 
stabilized by the antisense transcript Wrap53 (WD40-encoding RNA antisense to p53), a 
natural antisense RNA encoded by the Wrap53 gene located on chromosome 17, directly 
overlapping the first exon of p53135. The coding sequence of p53 mRNA also regulates p53 
expression. The Mdm2 protein binds to nucleotides corresponding to amino acids 15-26 of 
p53 mRNA, a binding that both enhances p53 translation and inhibits the E3 ligase activity of 
Mdm2 (which in turn prevents p53 degradation), thus increasing p53 protein levels in several 
ways136.  This is somewhat surprising considering the well-established role for Mdm2 as a 
negative p53 regulator, and emphasizes the complexity of the regulatory networks controlling 
p53 levels and activity.                                                         *  Paralogue: a homologue (similar protein/RNA) within the same species. # Transposons are mobile elements in the DNA, able to move from one site in the genome to another – causing 
risk of mutations and alterations of the DNA in the process.  
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Role of p53 in posttranscriptional gene regulation 
 
Interestingly, p53 itself can also regulate post-transcriptional gene regulation in several ways. 
p53 activates transcription of the miRNAs miR-34a, b and c that can trigger apoptosis (miR-
34a), and reduce cell growth and/or induce cellular senescence (all of the miR-34)137-141. p53 
also induces the transcription of the tumor suppressive miR-145142. In addition, p53 was 
recently shown to transcriptionally repress the miR-17-92 cluster after activation by 
hypoxia143. Further, loss of miRNA biogenesis in Dicer knockout mice activates p53 by 
upregulation of p19ARF (mouse homologue of p14ARF), resulting in p53 dependent 
senescence144. p53 can also enhance the biogenesis of several growth-inhibitory miRNAs 
post-transcriptionally by interacting with Drosha36. p53 may itself engage in regulation of 
5’UTRs – according to one study, p53 can inhibit its own translation by binding to its 
5’UTR145. Similarly, p53 has been shown to bind to the 5’UTRs of CDK4146, and FGF-2 
147,148 and inhibit their IRES-dependent translation. 
 
After this introduction to p53 and to mRNA regulation, I will move on to the p53 target gene 
involved in mRNA regulation that has been the focus of my studies – Wig-1. 
 
 
Wig-1 – gene structure and expression 
 
Wig-1 (for wild type p53-induced gene 1; also known as PAG608 and ZMAT3) is a direct 
transcriptional target of p53149-151. Human Wig-1 maps to 3q26.3-27, and the NCBI database 
contains two transcript variants of the Wig-1 gene. Isoform 1 (NM_022470) has a shorter 
5’UTR due to lack of exon 2, and also has one extra amino acid in the C-terminal domain as 
compared to isoform 2 (NM_152240) due to alternative splice site usage. The Wig-1 ORF of 
866 or 869 nucleotides (corresponding to proteins of 288 or 289 amino acids) is followed by a 
very long 3’UTR with three polyA sites (usage of the most distal gives an eight kb long 
3’UTR). Apart form the full-length protein translated from the first ATG residing in a 
relatively weak context, there is a downstream in-frame ATG that can be used for 
translational initiation, giving rise to a protein lacking the 20 most N-terminal amino acids. 
The presence of an upstream ATG, usage of which translates into an out-of frame ORF that 
terminates downstream of the first in-frame ATG, suggests that the translation of this upORF 
would favor usage of the downstream in-frame ATG for translation of the Wig-1 protein152. 
The Wig-1 gene structure – two in-frame ATGs and an out-of-frame upORF – is conserved in 
mouse and chicken152. Human Wig-1 has a perfect consensus p53 response element in intron 
1 (Wilhelm and Hellborg, unpublished results) and mouse Wig-1 contains two functional, but 
not absolute consensus, p53 response elements in the promoter region153. The Wig-1 protein 
contains a nuclear localization signal and three zinc fingers of the Cys2His2 type. The zinc 
fingers are unusual in their inter-histidine distance within the zinc fingers (five amino acids 
instead of the normal three to four) and their long linkers between the zinc fingers (56-75 
amino acids compared to six to eight as in most other zinc finger proteins). See figure 5 for an 
illustration of Wig-1 gene and protein structure. Wig-1 is very highly conserved down to fish, 
especially with regard to the zinc fingers that are almost perfectly conserved. The unusual 
zinc finger structure is shared with a small group of double stranded RNA (dsRNA) binding 
proteins that lack consensus dsRNA-binding motifs. The most well-studied member of this 
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group is JAZ, a protein that binds to the dsRNA nuclear export receptor Exportin-5154, and 
can positively regulate p53 transcriptional activity by binding to the p53 protein155. We have 
found Wig-1 expression in all cell lines tested to date (U2OS, MCF7, HeLa, ME-180, HCT 
116 p53 +/+ or -/-, H1299, Saos2, SK-N-BE(2), Kelly, SHSY-5Y, SKNAS, HEK-293, IMR-
90, human primary fibroblasts (HDF), and NIH-3T3) regardless of p53 status; however Wig-1 
levels are enhanced after stress due to activation of p53 (unpublished results). 
  
Figure 5: Human Wig-1 gene and protein structure. Asterisk indicates exon2, which is present in isoform 2 but 
not 1. dwnATG indicates the downstream in frame ATG. Extra CAG indicates the extra amino acid that is 
included in isoform 1 but not 2, due to alternative splice site usage. polyA indicates polyA site. ZF stands for 
zinc finger and NLS for nuclear localization signal.     
 
 
Wig-1 is an RNA binding protein 
 
In accordance with the function of its family member JAZ, Wig-1 is an RNA binding protein. 
Wig-1 binds both to longer dsRNA – a probe of around 130 bp was used in156 – and to shorter 
RNA of 21 bp. In the latter case, Wig-1 only binds to short RNA that resemble miRNA, i.e. 
have a two-nucleotide 3’ overhang. Both the first and second zinc finger of Wig-1 are 
necessary for binding to dsRNA in living cells156,157.  
 
 
Wig-1 and stem cells 
 
Wig-1 may be involved in stem cell maintenance and support. One study, comparing genes 
enriched in both haematopoietic, neuronal and embryonic stem cells (compared to the 
corresponding differentiated cell types) found Wig-1 upregulated in all three stem cell 
compartments, indicating a role for Wig-1 in stem cells158. Another study showed 
upregulation of Wig-1 in haematopoietic stem cells null for Bmi-1, a factor necessary for the 
renewal of these cells159. 
 
 
Rat Wig-1: PAG608 
 
The rat homologue of Wig-1 is constitutively expressed at relatively high levels in various 
regions of the rat nervous system, and has been shown to be induced in nervous system by a 
number of stress agents, including ischemia160,161, treatment with methamphetamine162, onset 
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of disease in a model of ALS163, and by L-DOPA in a Parkinson model164. Some studies also 
suggest pro-apoptotic functions of PAG608 in stressed brain160,165. Taken together, these data 
indicate a role for PAG608/Wig-1 in neurological pathologies and stress responses.  
 
 
For reasons that will later on become apparent, we will here take a quick detour to cover the 
RNA binding proteins RHA and hnRNPA2/B1 
 
 
hnRNPA2/B1 and RHA 
 
RNA Helicase A (RHA; also known as Nuclear DNA Helicase II) is a helicase unwinding 
both RNA and DNA. Its Drosophila homologue, MLE (maleless), is essential for maintaining 
the X chromosome hypertranscriptional*. In mammals RHA is involved in transcriptional 
regulation, for example by bridging the transcriptional co-activators CBP/p300 to RNA 
polymerase II166-168. (Reviewed in169). In addition, RHA has been shown to participate in the 
translation of selected mRNAs by recognizing a 5’UTR control element170.  
 
Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1) are highly abundant, RNA-
binding proteins derived from the same gene and differing by only 12 amino acids, due to the 
presence of exon 2 in the B1 transcript171. They are truly multitasking and their functions 
include packaging of nascent RNA, telomere biogenesis/maintenance, transcription, 
alternative pre-mRNA splicing, nuclear import and export, cytoplasmic trafficking of mRNA 
and regulation of translation (reviewed in172). hnRNPA2 has also been shown to be an ARE-
BP capable of binding to AREs in the 3’UTRs of glucose transporter 1173 and β -actin174, 
affecting their mRNA stability and turnover. 
 
 
From the title of my thesis it should be obvious that p53 is not the only famous transcription 
factor in Wig-1’s acquaintance. We will now move on to the world of Myc. 
 
 
Myc 
 
Myc, as p53, is a tumor-associated gene with long history. The founding member of the Myc 
family, c-Myc, was first identified some 30 years ago as the cellular counterpart of the avian 
myelocytomatosis virus oncogene175. The Myc family later expanded when N-Myc176,177 and 
L-Myc178 were discovered in the beginning of the 1980’s. While c-Myc is widely expressed in 
adult tissues, both of its cousins are almost exclusively expressed during embryonic 
development. (Reviewed in175,179-181). Still, their function is widely overlapping; hence in this 
text I will refer to all the family members jointly as “Myc”, unless otherwise specified. 
                                                         * Hypertranscriptional means exactly what it sounds like – the transcription increases. This renders the 
transcriptional output from the male one X chromosome on pair with that of the two X chromosomes of the 
female. This is how it’s done is in flies – in mammals instead, one of the female X chromosomes is 
transcriptional inactive, and here RHA does not seem to be play a role. 
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Myc is a transcription factor 
 
Myc is a transcriptional activator of the basic helix loop helix leucine zipper type*, and binds 
DNA in a heterodimer with its obligate partner Max. Myc and Max recognizes the so-called 
E-box sequence, the consensus of which is CACGTG. Even though Myc is absolutely 
dependent on Max for its function as a transcriptional activator, Max is not so faithful, but can 
also heterodimerize with other proteins such as Mad. Mad-Max heterodimers function as 
transcriptional repressors of E-boxes, thus opposing Myc function. Myc activates 
transcription by interacting with TRRAP (transactivation/transformation associated protein). 
Through TRRAP, Myc can recruit histon acetylation transferases responsible for acetylating 
the histones that DNA is wrapped around when packed in chromatin. Apart from TRRAP, 
Myc can also interact with a number of co-activator complexes that will induce other histone 
modifications. These modifications lead to the loosening up of chromatin structure, thus 
rendering the promoter in question more accessible for transcription. There seem to be few, if 
any, genes that rely exclusively on Myc for their transcription; rather, Myc tweaks the 
transcriptional landscape to a more favorable state, increasing the possibility for transcription 
to occur. Apart from its function as a transcriptional activator, Myc can also act as a 
transcriptional repressor, however in this case it does not act through E-boxes. (Reviewed 
in175,179-181). 
 
 
What does Myc do? 
 
The more appropriate question would be “What does Myc not do?”. The E-box sequence is 
found at every 4000 bp of the genome. Many of these E-boxes are non-functional, but Myc is 
still estimated to regulate 10-15% of all genes182,183. Myc has a vast and extremely diverse set 
of targets, including genes transcribed by all three RNA polymerases – protein coding genes 
as well as various functional RNA molecules. (Reviewed in179,180). Myc regulates the cell 
cycle by transactivating several cyclins and CDKs, as well as inhibiting cell cycle arrest genes 
such as p21 (reviewed in181). This regulation leads to shortened G1 phase and enabling of G1 
to S transition184,185. Further, Myc regulates cell growth in many different ways. It activates 
targets that increase the supply of the various molecules required for the cell to grow. It 
induces transcription of ribosomal genes – both those of ribosomal proteins and ribosomal 
RNA186, and can in that way boost the cell’s protein production. It also transactivates many 
genes involved in metabolism, leading to increased energy production. (Reviewed in181). 
Apart from these and many other potentially oncogenic Myc activities (such as promoting 
angiogenesis and metastasis), Myc can also induce apoptosis. Surprising as this may seem, it 
makes sense that Myc, being such a powerful cellular gas pedal, comes with an emergency 
brake. Myc induces apoptosis by transactivating p14ARF, which activates p53 through 
binding to and inhibiting Mdm2187. This mechanism implies that in order for Myc to 
transform cells, the apoptosis pathway needs to be somehow perturbed, for example by p53 
mutation or Mdm2 overexpression. (Reviewed in 175,179,181). However, lower Myc levels are 
required for driving proliferation than are needed for inducing apoptosis – probably to enable                                                         * This refers to the structural elements in Myc involved in DNA binding. 
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Myc’s physiological activities without killing the cell – but this dose dependency may render 
the Myc emergency brake somewhat inefficient188.   
 
 
Myc deregulation in cancer 
 
Myc is deregulated in a majority of cancers in various ways. Myc can be activated by viral 
transduction – which is how it was discovered in the first place – meaning that viruses either 
carry their own copy of Myc or that they integrate in the host genome in a way that activates 
endogenous Myc. Myc can also be activated by chromosomal translocations*, found in 
Burkitt’s lymphoma. These translocations put c-Myc (on chromosome 8) next to 
immunoglobulin heavy or light chains (on chromosome 14, 2 or 22) in B-cells, and c-Myc 
ends up under the control of the immunoglobulin regulatory elements. Since B-cells are 
specialized in making antibodies, they produce very high amount of immunoglobulins, and 
the simultaneous regulation of the c-Myc gene leads to very high c-Myc levels as well. A 
third mechanism for Myc activation is gene amplifications – especially frequent for N-Myc in 
neuroblastoma, but also seen in other cancers such as lung cancer, where any of the Myc’s 
can be amplified. (Reviewed in175,180).  
 
 
Regulation of Myc expression 
 
Myc is an immediate early gene, meaning that its gene expression is induced very rapidly 
upon stimulation with growth inducing signals. Conversely, anti-proliferative stimuli lead to a 
rapid shutdown of Myc expression. Transcription alone cannot explain the full change in Myc 
levels after growth “on or off” signals189. Both c-Myc and N-Myc are regulated through AREs 
in their 3’UTRs190-195. Further, the Myc 3’UTR is targeted by miRNAs. Both c-Myc and N-
Myc are targeted by miR-34196,197, and c-Myc is also a target of miR-145142 (interestingly, 
both these miRNAs are transcriptional targets of p53137-142) and of miR-24198 and let-7126. 
Further, the well known ARE stabilizer HuR, which can bind to the Myc AREs, actually 
represses c-Myc expression in a mechanism dependent on the miRNA let-7, presumably by 
recruiting let-7 to a target site adjacent to the HuR binding site126. c-Myc mRNA is also 
regulated through a coding region determinant RNA element in the coding region199. c-Myc 
protein levels are subject to proteasomal degradation induced by the E3 ligases Skp2 and 
Fbw7, and N-Myc is likewise targeted by the E3 ligase HectH9/Huwe1 (reviewed in180).  
 
 
Myc and stem cells, differentiation, and embryonic development  
 
c-Myc knockout mice die at E10.5# demonstrating multi-organ failure and general delay in 
development200. N-Myc knockout mice die before E11.5 and are also subject to delayed                                                         * A chromosomal translocation means that two chromosomes break and are glued together with each other – 
resulting in two new, “hybrid” chromosomes.  # The days of embryonic development in mice are denominated “E” (for embryonic day) followed by a number, 
always ending with .5. This is because in order to keep track of the embryonic days, mice are put up for mating 
(i.e. male and female are put together) in the evening, and – hopefully, if the mood is right – do their thing 
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growth, in combination with defects in nervous system, lung and heart201-204. L-Myc 
knockouts, however, are viable without any obvious phenotype205. In addition to the clear role 
in gross embryonic development thus demonstrated by c-Myc and N-Myc, these two Mycs 
are also implied in stem cell biology. N-Myc is important for the maintenance of neurological 
stem cells206 and c-Myc is necessary for the development of T-cells beyond the point when N-
Myc expression in these cells is diminished207. Further, adult haematopoietic stem cells 
double knockout for both c- and N-Myc are not viable208. Myc has also been implicated in the 
reprogramming of somatic cells to inducible pluripotent stem cells, iPSCs209. Some somatic 
cells can be changed into iPSCs with the combined introduction of a few factors, of which 
Myc is one. Taken together, these observations indicate a crucial role for Myc in stem cells, 
confirmed by the phenotype of embryonic stem cells (ESCs) double knockout for both c- and 
N-Myc. These ESCs demonstrate reduced proliferation and survival, and when injected into 
blastocysts in an attempt to create chimaeric embryos* they either failed to generate embryos 
altogether, or in some cases generated embryos with very serious malformations. Thus, Myc 
function is necessary already at the pre-blastocyst stage of embryonic development210 
(reviewed in 211).  
 
 
N-Myc and neuroblastoma 
 
Neuroblastoma is the most frequently diagnosed cancer among infants, and is responsible for 
15% of deaths in childhood cancer212. It arises in the neural crest# derived precursors or 
immature cells of the sympathetic nervous system§. It is generally located in the adrenal gland 
or in a paraspinal location in the abdomen or chest213,214. N-Myc amplification occurs in 20-
30% of neuroblastoma and is the most consistent marker of poor prognosis and aggressive 
disease (see fig. 6). It relates to poor outcome even in tumors with otherwise favorable disease 
patterns (such as localized disease)212,214,215. Further, mice overexpressing N-Myc in neural 
crest derived cells develop neuroblastoma, demonstrating that N-Myc expression can drive 
neuroblastoma formation216. Neuroblastoma may spontaneously differentiate213, and it has 
been demonstrated that N-Myc knockdown using siRNA in neuroblastoma cells harboring N-
Myc amplifications can induce cancer cell differentiation and apoptosis217.   
    
                                                        
during the following night. The next day will then be half a day of embryonic development, E0.5. The next day 
again will be E1.5, and so on. From this we learn that scientists, contrary to common belief, prefer not to dissect 
small animals during the night (the embryos removed would then be E followed by a whole number) but instead, 
whenever possible, work daytime. * To make a knockout or knock-in mouse, the desired manipulations are carried out in ESCs, which are then 
injected into a blastocyst followed by implantation of the blastocyst in a female. The resulting embryo will have 
tissues generated both from the blastocyst cells and from the injected ESCs – a chimera. # The neural crest is a transient embryonic tissue in the developing nervous system. It arises from ectoderm 
when the neural tube closes (ectoderm is the outermost cell layer in the gastrula stage of the early embryo, and 
the neural tube is the embryo precursor of the central nervous system).  § The sympathetic nervous system is a part of the autonomous nervous system responsible for the stress (“fright-
and-flight”) response.   
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Figure 6: Probability of event free survival (EFS) in neuroblastoma patients with or without N-Myc 
amplification. From Scmidt et al., J.Clin.Oncol, 2000215.
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Aims of this thesis 
 
The overall question asked in my thesis can be summarized in one very short sentence – 
“What does Wig-1 do?”. Answering this question is important not only to learn more about 
Wig-1 itself, but also for gaining further insight into the function of the p53 tumor suppressor. 
Since p53 exerts its function mainly through transactivation of target genes, we must 
understand the function of these targets is order to fully understand the function of p53.  
 
 
Specific aims of the papers: 
 
Paper I ‐ To identify proteins interacting with Wig-1 
 
Paper II ‐ To investigate the mechanism of, and function for, Wig-1 mediated regulation of p53 
 
Paper III ‐ To study Wig-1 regulation of another ARE-containing mRNA – that of N-Myc – and the 
functional significance of this regulation 
 
Paper IV ‐ To determine the role of Wig-1 in embryonic development 
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Results and Discussion 
 
 
Paper I 
 
At the outset of this paper little was known of the Wig-1 function. We knew that it was an 
RNA binding protein156,157, however, earlier studies were based on assumptions made from 
the structural resemblance of Wig-1 to other RNA binding proteins and had been performed 
mainly in vitro. Albeit excellent approaches, these studies presented Wig-1 with RNA and 
analyzed binding or no binding, without addressing how important RNA binding is for the 
function of Wig-1 in living cells. Further, we knew that Wig-1, when overexpressed 
transiently, could somewhat reduce cell growth over longer periods of time150. To better be 
able to study the importance of Wig-1 RNA binding for Wig-1 function in vivo, we generated 
stable Saos-2-Tet-ON cells that overexpressed FLAG-tagged Wig-1, either wild-type or 
RNA-binding deficient zinc finger point mutants, after addition of doxycycline. We found 
that wild type but not mutant Wig-1 could inhibit cell growth modestly in long-term assays 
without any effect on cell cycle or cell death. Further, we used the FLAG-tagged Wig-1 to 
immunoprecipitate Wig-1 and identify co-purified proteins. In this way we found RHA and 
hnRNPA2/B1 to be bound to Wig-1 in an RNA dependent fashion.  
 
Since both RHA and hnRNPA2/B1 are abundant RNA binding proteins with many roles in 
RNA function, biogenesis, and turnover in the cell (reviewed in169,172) it is hard to make any 
guesses of the function of Wig-1 based on its interactions with these proteins. However, 
knockdown of hnRNPA2/B1 using siRNA had been reported to cause G1-arrest and reduction 
in cell proliferation218, and at this time we had started knocking down Wig-1 and noted a 
similar effect. To investigate this further, we knocked down either one alone or both together, 
and analyzed cell proliferation and cell cycle. We could conclude that knocking down both 
together had the same effect as knocking down either one alone – absence of an additive 
effect indicating that Wig-1 and hnRNPA2/B1 may function in the same pathway to affect 
cell cycle and cell viability.  
 
In conclusion, from this study we learned that Wig-1 interacts with RHA and hnRNPA2/B1 
through RNA. Whether this indicates a functional interaction, or if they just happen to sit on 
the same RNA frequently, remains to be shown. However, the fact that knock-down of either 
hnRNPA2/B1 or Wig-1 has the same effect on cell viability as knocking down both together 
suggests that these two proteins may share at least some functions. 
 
Further, we found that both too much or too little Wig-1 has negative impact on cell viability, 
demonstrating the need for the cell to keep Wig-1 levels within appropriate range. 
 
Even though this study failed to pin down an exact function of Wig-1, it demonstrated that 
RNA binding is important for Wig-1 in vivo. We performed an unbiased approach to 
investigate Wig-1 interactions, instead of assuming that these interactions were based on 
RNA. Still we came up with RNA binding as a key element, since the Wig-1 interaction 
partners identified bound Wig-1 through RNA. Also, we found that long-term overexpression 
of Wig-1 could decrease cell viability somewhat, but only if the Wig-1 used retained its RNA 
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binding ability. Clearly, the RNA binding capacity of Wig-1 is crucial for its function in 
living cells.  
 
 
Paper II 
 
This study started with the observation that Wig-1 knockdown using siRNA led to reduced 
p53 protein levels. We first confirmed that Wig-1 could positively regulate p53 protein levels 
both in unstressed cells and after p53 activation by DNA damage. We then investigated how 
this regulation affected the p53 stress response. Since both overexpression and knock-down of 
Wig-1 could decrease cell viability (Paper I) we performed these functional assays in a setting 
were we could analyze the effects of knocking down or overexpressing Wig-1 in p53 wild-
type compared to p53 null isogenic cell lines. We took this approach to be able to separate the 
effect of Wig-1 on the p53 response to any other, p53 independent, effects of Wig-1. In this 
way, we could demonstrate that overexpression of Wig-1 potentiated the ability of p53 to 
inhibit colony formation after exposure to the DNA damaging agent camptothecin in HCT 
116 cells, and that knockdown of Wig-1 reduced the p53 response to the DNA damaging 
agent mitomycin C in MCF7 cells.  
 
Next, we set out to investigate the mechanism behind the Wig-1 regulation of p53. Since 
Wig-1 is an RNA binding protein156,157 and RNA binding is important for its function (Paper 
I) we investigated if Wig-1 knockdown could affect the p53 mRNA. Indeed it could – p53 
mRNA levels were decreased in the absence of Wig-1. We could further demonstrate that 
Wig-1 stabilizes the p53 mRNA by preventing its deadenylation, the first and rate limiting 
step in mRNA degradation (reviewed in93). Since mRNA degradation primarily takes place in 
the cytoplasm (reviewed in93), and exogenous Wig-1 was reported to be mainly nuclear150,156, 
we investigated the localization of endogenous Wig-1 in detail. We found that Wig-1 is both 
nuclear and cytoplasmic, is able to shuttle between these two compartments, and is 
upregulated in both compartments after stress. 
 
p53 mRNA contains two AREs: one U-rich stretch and one element containing the AUUUA 
pentamer98,99. p53 mRNA stability102 and translation98 are regulated through these regions, 
which prompted us to investigate if they were also implied in Wig-1 mediated regulation of 
p53 mRNA. We found that Wig-1 indeed binds to the U-rich ARE in p53 3’UTR, and 
regulates p53 mRNA stability through this region. 
 
Our findings presented in this paper demonstrate that the p53 target Wig-1 acts in a positive 
feedback loop stabilizing p53 mRNA. We show that Wig-1 is important for maintaining the 
basal p53 mRNA levels, and also acts to augment the p53 response to cellular stress. This 
Wig-1-mediated stabilization of p53 mRNA may ascertain a sustained p53 response. Wig-1 
can keep the p53 mRNA levels high enough to enable robust de novo protein synthesis, thus 
replacing the p53 degraded by Mdm2. In agreement with a role for Wig-1 in augmenting the 
p53 response, Wig-1 knockdown in rat neurons attenuates methamphetamine-induced p53-
dependent cell death162. 
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The fact that Wig-1 regulates p53 through binding to an ARE told us much about Wig-1 
function – this finding placed Wig-1 among the ARE binding proteins that regulate mRNA 
stability and translation. Since most ARE binding proteins have multiple targets (reviewed 
in94,97) we hypothesized that this was true also for Wig-1. We performed a preliminary screen 
where we knocked down Wig-1 and investigated the levels of a number of proteins derived 
from ARE regulated mRNAs. In this screen we found c-Myc protein levels to be decreased 
upon Wig-1 knockdown – a finding that has kept us busy since.  
 
 
Paper III 
 
In paper II, we established that Wig-1 is an ARE-BP and found that knockdown of Wig-1 
leads to decreased levels of c-Myc. Since both c-Myc and its family member N-Myc are 
regulated through AREs192,193, we went on to investigate if N-Myc was regulated by Wig-1 as 
well. We knocked down Wig-1 in neuroblastoma cell lines carrying amplified N-Myc and 
found N-Myc protein levels to be decreased. This led to a more careful study of Wig-1 and N-
Myc in neuroblastoma. We found that Wig-1 positively regulates N-Myc protein and mRNA 
levels and that Wig-1 binds to the 3’UTR of N-Myc and regulates it through an AU-rich 
region in the 3’UTR. N-Myc knockdown can lead to differentiation in SK-N-BE(2) cells217, 
and thus we set out to investigate if Wig-1 knockdown could give a similar phenotype. And 
that was indeed the case – after Wig-1 knockdown for four days we could detect 
morphological changes associated with differentiation, G1-arrest, and upregulation of the 
differentiation marker NPY219, comparable to what we observed upon N-Myc knockdown. 
This effect of Wig-1 on differentiation was dependent on N-Myc, since Wig-1 knockdown in 
another differentiation-competent neuroblastoma cell line lacking N-Myc expression (SHSY-
5Y) did not induce differentiation. 
 
This study raised the question why the p53 target gene Wig-1 would positively regulate an 
oncogene such as N-Myc. It is conceivable that Wig-1 acts independently of p53 during 
embryonic development, which is the major time for physiological N-Myc expression212,214.  
It is also plausible that Wig-1 target specificity may change after stress. Wig-1 targets a U-
rich element in p53 mRNA and an AU-rich element in N-Myc mRNA, suggesting that the 
interaction of Wig-1 with the two AREs may be differently regulated. A third possibility is 
that Wig-1 belongs to the category of p53 target genes that promote survival (reviewed in63). I 
will get back to these questions in the final discussion.  
 
Since loss of Wig-1-mediated regulation of N-Myc leads to differentiation of N-Myc 
amplified neuroblastoma cells there could be a therapeutic potential in interfering with this 
regulation. In tumors with mutant p53, decreasing Wig-1 levels or blocking Wig-1 RNA 
binding could be beneficial. In tumors with wild-type p53, it would be desirable to somehow 
direct Wig-1 away from the AU-rich element of N-Myc and instead increase its binding to the 
U-rich element of p53. Such a strategy would in one sweep remove the driving oncogene – N-
Myc – and stabilize the killer – p53.  
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Paper IV 
 
To gain further insight in the biological function of Wig-1, we set out to investigate the role of 
Wig-1 during embryonic development. First, we investigated Wig-1 expression in mouse 
embryos. We found Wig-1 to be expressed at high levels early during embryonic development 
(the earliest time point investigated by us was E5.5, but data from microarray studies indicate 
Wig-1 expression also before this point220). Levels then dropped somewhat to peak again at 
E10.5-13.5, after which point the expression decreased markedly. Immunohistochemistry 
revealed that Wig-1 is most highly expressed in brain and nervous system and in the fetal 
liver at E10.5-E13.5. Further, Wig-1 expression is independent of p53 during embryonic 
development, at least in unstressed embryos at E10.5 and E13.5, as revealed from 
immunohistochemistry of p53 knockout embryos.  
 
To further study Wig-1 during embryonic development we generated Wig-1 knockout mice 
by targeted deletion of part of exon 2 and exon 3 and 4. The upstream ATG generating an 
upORF152 was also mutated. We obtained germ line transmission form the injection of two 
separate ESC lines at a total of three times (one cell line was injected twice). The resulting 
chimaeric and heterozygous mice were phenotypically normal, although we acquired less than 
Mendelian ratio of heterozygous offspring from intercrossing heterozygous with wild type 
mice (around 37% instead of the expected 50%). Further, when intercrossing heterozygous 
mice with each other we could not detect any Wig-1 null offspring, indicating that Wig-1 
knockout causes embryonic lethality. We obtained and genotyped embryos from different 
embryonic days but were unable to detect any knockout embryos at any point investigated. 
This directed out attention to the earliest phase of embryogenesis – the pre-implantation 
period from the zygote to the blastocyst stage of 32-64 cells. This phase normally takes 3.5 
days in mouse. To determine if the knockout embryos were present at blastocyst stage, we 
performed in vitro fertilization (IVF) and grew zygotes in culture until they reached blastocyst 
stage, followed by genotyping of the blastocysts. Still, we found no knockout blastocysts, 
indicating that homozygous Wig-1 knockout in mice is lethal already before this time.  
 
Mice knockout for the ARE-BP HuR were recently shown to die during embryonic 
development due to deregulation of several HuR targets127. Since we had shown Wig-1 to be 
an ARE-BP (Paper II and III), we asked whether the lethality observed in the Wig-1 
knockouts could be explained in terms of deregulated Wig-1 targets. We knew that Wig-1 
regulates N-Myc mRNA through and AU-rich region and that Wig-1 knockdown leads to 
decreased N-Myc mRNA and protein levels (Paper III). Further, we had shown that Wig-1 
knockdown could decrease c-Myc protein levels (Paper II). Myc function seems to be 
required for the survival of ESCs and early embryonic development. c-Myc and N-Myc are 
redundant in ESCs and in the early embryo up until the point when Myc expression 
diverges221. A recent paper210 demonstrated that the simultaneous knockout of both c-Myc 
and N-Myc in mouse ESC led to decreased survival and pluripotency and increased 
differentiation of these cells. When these ESCs were injected into blastocysts they either 
failed to generate any embryos or in some cases generated embryos with severe defects. This 
study is further supported by the finding that mice knockout for Max, the obligate partner for 
Myc, die at E6.5. Their lethality coincides with loss of maternal Max222, indicating that 
Max/Myc function is required also before this stage. Therefore, we hypothesized that the 
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combined deregulation of c- and N-Myc could be the cause of the very early embryonic lethal 
phenotype of the Wig-1 knockout mice, and thus set out to confirm that Wig-1 does indeed 
regulate c-Myc. We showed that Wig-1 knockdown leads to decreased c-Myc mRNA and 
protein levels, and conversely, ectopically expressing Wig-1 increases c-Myc levels. Further, 
Wig-1 could bind to the 3’UTR of c-Myc, indicating that the regulation is mediated by an 
ARE in the c-Myc 3’UTR.  
 
Interestingly, there is a mouse model where the c-Myc 3’UTR has been knocked out with 
retained c-Myc 5’UTR and coding region. This mouse is perfectly viable, arguing against an 
important role for regulation of the c-Myc 3’UTR during embryonic development223. 
However, AREs are generally considered to be destabilizing elements (reviewed in97), 
therefore, removing them may not result in a phenotype because c-Myc lacking its 3’UTR is 
stable and will be expressed at adequate levels for embryonic development to proceed. On the 
other hand, once the AREs are present, it may be necessary to keep them stabilized by the 
action of a protein such as Wig-1 in order to sustain c-Myc expression. 
 
In addition to an effect in the pre-implantation embryo, loss of Wig-1 may affect germ cells, 
giving rise to low quality of Wig-1 negative oocytes and/or sperms. A role for Wig-1 in germ 
cells is in line with evidence from microarray studies (PubMed GeoProfiles GDS2112 and 
GDS1677), which show upregulation of Wig-1 in germ cells upon stimulation with growth 
factors. Evidence that Wig-1 is expressed from oocyte to blastocyst (with a peak in early 
blastocysts) can also be found in microarray data from Guo et al., Develop. Cell, 2010220. The 
same study reports expression of all the three Myc family members at these stages, and their 
expression pattern overlaps with that of Wig-1. The role of Myc in germ cells is not 
completely elucidated, but reports suggests that c-Myc is expressed during spermatogenesis224 
and that N-Myc plays an essential role for spermatogonial stem cell proliferation225. Further, 
c-Myc is expressed and may be involved in oocyte maturation226,227, and at least Xenopus* c-
Myc may be subjected to ARE-dependent degradation in oocytes, fertilized eggs, and early 
embryos228,229. Since Myc loss impairs survival already in the ESCs210, it would not be 
surprising if decreased Myc levels could have a negative effect on germ cells. Alternatively, 
Wig-1 could regulate other ARE-containing mRNA in the germ cells, whose deregulation in 
the heterozygote Wig-1 cells could cause defects and/or death in these cells. ARE mediated 
regulation is important in late oocyte maturation and early embryonic development. At these 
stages, the oocyte/embryo genome is transcriptionally silent, and translation is sustained by 
maternal mRNAs. These mRNAs must be kept stable from the 2nd meiotic division, to which 
stage the oocyte develops during puberty and then arrests and stops transcription, until the 
embryo genome is activated (at the 2nd cell division in the mouse), which may happen months 
or even years later. Most maternal mRNAs are degraded in the late stage oocyte, but some 
that are crucial for the earliest embryonic development are retained until after embryo genome 
activation. AREs are important for regulating stability of these retained maternal mRNAs128. 
If Wig-1 is haploinsufficient, decreased Wig-1 levels in the oocyte can lead to deregulation of 
a number of these maternal mRNA required immediately before and after fertilization. In the 
case of defect Wig-1 heterozygote germ cells, the wild-type germ cells will take over, which                                                         * Xenopus is a frog, good for research because of its huge, easy-to-manipulate eggs.   
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could explain our observation of skewed ratio of heterozygous versus wild type animals in 
normal litter sizes.   
 
In conclusion, in this paper we show that Wig-1 knockout mice die during embryonic 
development before blastocyst stage, probably caused by deregulation of Wig-1 targets such 
as c-Myc and N-Myc. 
 
 
What does Wig-1 do?  
 
Combined discussion of all papers 
The results presented in this thesis demonstrates that Wig-1 is and ARE-BP, a protein that 
binds to and regulates mRNA through AREs in the 3’UTRs of its target mRNAs. We have so 
far identified three Wig-1 targets – p53, c-Myc and N-Myc. This target spectrum raises the 
question why Wig-1 – a p53 target gene and stabilizer of p53 mRNA – positively regulates 
the Myc oncogenes? Why is Wig-1 fraternizing with the enemy? 
 
We propose three possible models to explain this Wig-1 target selection. First of all, it is 
possible that Wig-1 has a different set of targets in adult and in embryonic tissues – Wig-1 
may regulate p53 in adult cells while the Myc mRNAs may be preferred targets during 
development. Target specificity may also be deregulated during transformation, rendering the 
Mycs Wig-1 targets in cancer cells. A different subset of Wig-1 targets in adult and 
developing tissues could be achieved by selective expression of yet unidentified Wig-1 
cofactors. In accordance with a p53 independent role for Wig-1 during embryogenesis, we 
have shown that basal Wig-1 expression is independent of p53 during embryonic 
development. In addition, the phenotype of Wig-1 knockout mice differs markedly from that 
of p53 knockout mice – Wig-1 knockouts are lethal before blastocyst stage while p53 
knockouts mainly develop normally5. The fact that N-Myc is normally expressed only during 
embryonic development is also in line with a development-specific subset of Wig-1 targets. 
Arguing against this theory, however, is the observed Wig-1-mediated regulation of c-Myc in 
human primary fibroblasts indicating that Wig-1 can regulate c-Myc also in cells that are 
neither embryonic nor cancerous. See figure 7 a for an illustration.  
 
The second theory is based on a change of Wig-1 target selection after stress. One could 
imagine that a stress-induced cofactor exchange and/or post-translational modification of 
Wig-1 could induce target specificity to change from Myc to p53. In accordance with this 
theory, the Wig-1 protein has several putative phosphorylation sites (Bersani et al, 
unpublished data), and is acetylated in vitro (Mendez-Vidal et al, unpublished data). Also in 
this scenario, the fact that Wig-1 regulates p53 mRNA through a U-rich and N-Myc through 
an AU-rich region opens up the possibility of differently regulated Wig-1 specificity and/or 
different Wig-1 affinity for these two AREs. p53 mRNA is regulated by Wig-1 also in the 
absence of stress, which speaks against this model. However, it may be possible that Wig-1 
always is able to regulate the U-rich region in p53, while it only can regulate the AU-rich 
region in N-Myc in the absence of stress. See figure 7 b for an illustration.  
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Figure 7: Models for the role of Wig-1 mediated regulation of p53 and Myc. See text for details.  
 
 
The third possibility is based on the observation that p53 can induce a number of genes that 
prevent apoptosis and promote survival (reviewed in63). Lately, it has been realized that the 
p53 responses of cell cycle arrest and DNA repair on the one hand, and apoptosis on the other 
hand, actually can oppose each other. Mild damage induces cell cycle arrest and DNA repair, 
allowing the cell, once the damage is repaired, to return to a cycling state. In accordance with 
this, both p21 and 14-3-3σ are anti-apoptotic (reviewed in63,230). The perfect consensus p53 
response element in the human Wig-1 intron 1 supports a role of Wig-1 in a mild stress 
response. Perfect consensus p53 response elements are normally found in cell cycle arrest 
genes such as p21231. Additionally, Wig-1 induction after p53 activation has similar kinetics 
to that of p21149. Further support for a role of Wig-1 in an arrest associated response comes 
form a mouse model knock-in for a p53 mutant only able to activate cell cycle arrest genes. 
When MEFs from this mouse was treated with γ -radiation, Wig-1 was one of the most 
strongly upregulated genes232.  In a mild stress response, where p53 induces arrest and repair 
followed by return to cycling, it may be beneficial for p53 to also induce a gene – Wig-1 – 
that will stabilize the Myc mRNAs. This stabilization will provide the cell with a modest 
increase in factors necessary for proliferation. At the same time, Wig-1 also stabilizes p53 
mRNA, thus lowering the threshold for a response to subsequent stress in case of remaining 
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damage. Further, the low basal levels of p53 have functions differing from those of stress-
activated p53 and may actually promote survival (reviewed in16,63); hence Wig-1 may be one 
of these pro-survival targets of basal p53 levels. See figure 7 c for an illustration.  
 
 
Conclusions in summary 
 
Paper I 
Wig-1 binds to RHA and hnRNPA2/B1 through RNA. The RNA binding ability of Wig-1 is 
important for the biological functions of Wig-1. 
 
Paper II 
Wig-1 is an ARE-BP that acts in a positive feedback loop to stabilize p53 mRNA through 
binding to a U-rich region in the p53 3’UTR. 
 
Paper III 
Wig-1 positively regulates N-Myc mRNA through an AU-rich region in the N-Myc 3’UTR, 
and Wig-1 knockdown induces differentiation in N-Myc amplified neuroblastoma cells. 
 
Paper IV 
Wig-1 knockout mice are lethal before the blastocyst stage during embryonic development, 
possibly because of the simultaneous deregulation of c-Myc and N-Myc.  
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